FDA green­lights first made-in-Chi­na PD-1 as Jun­shi, Co­herus beat BeiGene to the punch

The first Chi­nese PD-1 is com­ing to the US mar­ket, as the FDA ap­proves tori­pal­imab in re­cur­rent or metasta­t­ic na­sopha­ryn­geal car­ci­no­ma (NPC) across all lines of treat­ment.

Jun­shi Bio­sciences — which back in 2018 be­came the first drug­mak­er to win ap­proval in Chi­na for a home­grown check­point in­hibitor — was the orig­i­nal de­vel­op­er of the drug. But Co­herus Bio­Sciences paid $150 mil­lion up­front in ear­ly 2021 for US and Cana­da rights. The an­ti­body, which is mar­ket­ed as Tuoyi in Chi­na, will be brand­ed as Lo­q­torzi in the US, with its launch planned for the first quar­ter of 2024.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.